QL1604 combined with bevacizumab as an innovative first-line treatment for HCC patient with extensive metastasis who showed remarkable effect: a case report

This case report discusses a 64-year-old male patient with recurrent and metastatic hepatocellular carcinoma (HCC) who experienced lower limb paralysis due to tumor invasion of the spinal canal. The patient was treated with a combination of QL1604 and bevacizumab. The patient's paralysis improved, motor function returned to normal, and the tumor shrank, achieving a state of partial response (PR) that lasted for one and a half years. The Frankel grade, used to assess spinal cord injury, improved from C to E. This new combined therapy of QL1604 and bevacizumab showed excellent efficacy and minimal side effects in this patient, suggesting it has potential as a first-line treatment strategy for HCC.

• 1
  The patient's paralysis symptoms gradually improved, and the motor function of the lower limbs completely returned to normal after treatment with QL1604 and bevacizumab.
• 2
  The tumor shrank to a state of partial response (PR) and lasted for one and a half years with the QL1604 and bevacizumab treatment.
• 3
  The patient experienced minimal side effects during the treatment with QL1604 and bevacizumab, indicating a good safety profile.